Skip to content
Bored Studies
RecruitingPhase 2

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Reunion Neuroscience Inc · NCT07489651

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–74 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
160
US sites recruiting
27
Study start
April 20, 2026
Record last updated
September 24, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Being studied: RE104 for Injection; Placebo

Conditions: Generalized Anxiety Disorder

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Has Generalized Anxiety Disorder as defined by DSM-5-TR
  • If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
  • Is willing and able to comply with the conditions and requirements of the study

Exclusion Criteria

  • Has a significant risk of suicide
  • Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
  • Has other concurrent psychiatric disorders that is the primary disorder.
  • Has other medically significant conditions rendering unsuitability for the study
  • Has used or will need to use prohibited medications or therapies
  • Has a known sensitivity or intolerance to study intervention or potential rescue medications

Recruiting US locations

  • University of Alabama (UAB) Clinical Research Unit (CRU)

    Birmingham, AL 35209

    Site contact: Seher Premani · spremani@uab.edu · spremani@uab.edu

  • Lighthouse Psychiatry

    Gilbert, AZ 85234

    Site contact: Matt Longson · 435-268-5800 · Contact@neosciclinicalresearch.com

  • Preferred Research Partners, Inc.

    Little Rock, AR 72211

    Site contact: Stacy Tierney · 501-553-9987 · stierney@preferredresearchpartners.com

  • Collaborative Neuroscience Research, LLC

    Garden Grove, CA 92845

    Site contact: CNS Outreach Department · 844-424-9494 · cns.outreach@cenexel.com

  • Kadima Neuropsychiatry Institute

    La Jolla, CA 92037

    Site contact: Angelica Lu · 858-775-2053 · angelical@kadimanp.com

  • Open Mind Therapeutics

    San Francisco, CA 94114

    Site contact: Victoria Vega · 415-906-7399 · victoria@openmindcollective.org

  • TRIP Clinic at Psychedelic Science Institute

    Santa Monica, CA 90404

    Site contact: Ashley Ramos · trialadmin@psychedlicsci.com

  • Innovative Clinical Research, Inc.

    Lauderhill, FL 33319

    Site contact: Melissa Rodco · 305-722-8444 · mrodco@segaltrials.com

  • University of South Florida

    Tampa, FL 33613

    Site contact: Genesis Estramera · 813-974-1404 · gestramera@usf.edu

  • Atlanta Center for Medical Research

    Atlanta, GA 30331

    Site contact: Amber Tannahill · 404-881-5800 · a.tannahill@cenexel.com

  • CenExel iResearch, LLC

    Decatur, GA 30030

    Site contact: Michael Mahaffrey · m.mahaffrey@cenexel.com

  • Evergreen Clinical Trials

    Norcross, GA 30092

    Site contact: Stephen Wheeler · 943-230-1385 · stephen@evergreenstrials.com

  • CenExel iResearch, LLC

    Savannah, GA 31405

    Site contact: Michelle Lagares · 912-744-0800 · M.Lagares@CenExel.com

  • Uptown Research Institute

    Chicago, IL 60640

    Site contact: Deborah Jones-Miller · 773-989-8313 · Djones-miller@uptownresearch.com

  • Henry Ford Medical Center - Columbus

    Novi, MI 48377

    Site contact: Madeline Bross · 248-344-7366 · mbross1@hfhs.org

  • Midwest Research Group

    Saint Charles, MO 63304

    Site contact: Lindsay vanWinkle · 636-946-8032 · lvanwinkle@midwestresearchgroup.com

  • UNM Research Program Psychedelic Therapies

    Albuquerque, NM 14624

    Site contact: Hector Garcia · 505-675-0582 · hecgarcia@salud.unm.edu

  • NYU-H+C Clinical and Translational Science Institute

    New York, NY 10016

    Site contact: Jillian Kelly · 212-404-7764 · Jillian.kelly@nyulangone.org

  • University of North Carolina at Chapel Hill

    Chapel Hill, NC 27514

    Site contact: Julia Hoffman · julia_hoffmann1@med.unc.edu

  • Neuro-Behavioral Clinical Research, Inc.

    North Canton, OH 44720

    Site contact: Crystal Blackford · 330-493-1118 · cblackford@nb-cr.com

  • Summit Headlands LLC

    Portland, OR 97210

    Site contact: Tyler Leecing · tyler.leecing@summitnetwork.com

  • University of Pennsylvania

    Philadelphia, PA 19104

    Site contact: Erin Blase · 215-746-6419 · erin.blase@pennmedicine.upenn.edu

  • Austin Clinical Trial Partners

    Austin, TX 78737

    Site contact: Kara Chilek · 512-521-0595 · studyinfo@austinCTP.com

  • BioBehavioral Research Austion

    Austin, TX 78759

    Site contact: Tracie Wesson · 402-934-0044 · tracie.wesson@qcrnetwork.com

  • Aim Trials, LLC

    Plano, TX 75093

    Site contact: Sonia Prashar · 214-856-2778 · sonia.prashar@aimtrials.com

  • Cedar Clinical Research

    Draper, UT 84020

    Site contact: Jane Bjorklund · 801-369-4219 · jane.bjorklund@numinusnetwork.com

  • Inner Space State Street

    Orem, UT 84058

    Site contact: Janet Jimenez · 801-871-5516 · apply@innerspaceresearch.com

Study contacts (from the official record)

  • Mark Pollack Chief Medical Officer, M.D. · 1-888-880-REUN · info@reunionneuro.com
All mental health studies in Alabama →
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder (NCT07489651) | Bored Studies